PTC Therapeutics, Inc. (PTCT) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $60.56 (-5.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Tiago Fauth | Raymond James | $108.00 | +78.3% |
| Feb 23, 2026 | Eliana Merle | Barclays | $120.00 | +98.2% |
| Feb 20, 2026 | Brian Abrahams | RBC Capital | $82.00 | +35.4% |
| Nov 5, 2025 | Tiago Fauth | Wells Fargo | $93.00 | +53.6% |
| Nov 5, 2025 | Gena Wang | Barclays | $68.00 | +12.3% |
| Oct 28, 2025 | Kelly Shi | Jefferies | $77.00 | +27.1% |
| Aug 8, 2025 | Joel Beatty | Robert W. Baird | $70.00 | +15.6% |
| May 7, 2025 | Joel Beatty | Robert W. Baird | $66.00 | +9.0% |
| Jan 7, 2025 | Brian Abrahams | RBC Capital | $58.00 | -4.2% |
| Nov 27, 2024 | Joel Beatty | Robert W. Baird | $52.00 | -14.1% |
| Oct 11, 2024 | Jeffrey Hung | Morgan Stanley | $45.00 | -25.7% |
| Aug 26, 2024 | Colin Bristow | UBS | $47.00 | -22.4% |
| Jul 12, 2024 | Jeffrey Hung | Morgan Stanley | $32.00 | -47.2% |
| May 20, 2024 | Paul Choi | Goldman Sachs | $32.00 | -47.2% |
| May 20, 2024 | Kelly Shi | Jefferies | $46.00 | -24.0% |
| Apr 26, 2024 | Jeffrey Hung | Morgan Stanley | $30.00 | -50.5% |
| Jun 23, 2022 | Brian Abrahams | RBC Capital | $46.00 | -24.0% |
| Apr 5, 2022 | Kristen Kluska | Cantor Fitzgerald | $63.00 | +4.0% |
| Aug 31, 2021 | Colin Bristow | UBS | $45.00 | -25.7% |
Top Analysts Covering PTCT
PTCT vs Sector & Market
| Metric | PTCT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.27 | 2.25 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | +69.9% | +153002.0% | +21.5% |
| P/E Ratio | 8.58 | 3.46 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $170M | $290M | $340M | 4 |
| 2027-03-31 | $145M | $248M | $291M | 4 |
| 2027-06-30 | $161M | $275M | $323M | 3 |
| 2027-09-30 | $171M | $292M | $343M | 3 |
| 2027-12-31 | $156M | $267M | $313M | 3 |
| 2028-12-31 | $1.34B | $1.34B | $1.34B | 8 |
| 2029-12-31 | $1.21B | $1.55B | $1.81B | 7 |
| 2030-12-31 | $1.32B | $1.69B | $1.98B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2027-03-31 | $-0.23 | $-0.19 | $-0.09 | 1 |
| 2027-06-30 | $-0.07 | $-0.06 | $-0.03 | 1 |
| 2027-09-30 | $0.05 | $0.10 | $0.12 | 1 |
| 2027-12-31 | $-0.55 | $-0.45 | $-0.21 | 1 |
| 2028-12-31 | $-3.90 | $0.72 | $3.40 | 7 |
| 2029-12-31 | $2.32 | $3.22 | $3.94 | 2 |
| 2030-12-31 | $3.03 | $4.21 | $5.16 | 5 |
Frequently Asked Questions
What is the analyst consensus for PTCT?
The consensus among 15 analysts covering PTC Therapeutics, Inc. (PTCT) is Buy with an average price target of $106.00.
What is the highest price target for PTCT?
The highest price target for PTCT is $120.00, set by Eliana Merle at Barclays on 2026-02-23.
What is the lowest price target for PTCT?
The lowest price target for PTCT is $30.00, set by Jeffrey Hung at Morgan Stanley on 2024-04-26.
How many analysts cover PTCT?
15 analysts have issued ratings for PTC Therapeutics, Inc. in the past 12 months.
Is PTCT a buy or sell right now?
Based on 15 analyst ratings, PTCT has a consensus rating of Buy (2.27/5) with a +69.9% upside to the consensus target of $106.00.
What are the earnings estimates for PTCT?
Analysts estimate PTCT will report EPS of $0.01 for the period ending 2026-12-31, with revenue estimated at $290M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.